Overcoming Barriers to Injectable Noninsulin Therapies
This CME/CE-accredited CME Snapshot™ four-part series is intended for endocrinologists, primary care providers (PCPs), and other health care providers involved in the identification, evaluation, and treatment of patients with T2DM. During these activities, two expert faculty will participate in a series of interactive discussions on recent evidence related to glucagon-like peptide 1 receptor agonists (GLP-1 RAs). The faculty will also review freely available patient- and caregiver directed educational resources that seek to improve shared decision-making.
These activities have been designed to meet the educational needs of endocrinologists, PCPs (eg, internists, family physicians, nurse practitioners, and physician assistants), and other clinicians who manage patients with T2DM.
Upon completion of these activities, participants should be better able to do the following:
- Dialogue with patients with T2DM about injectable noninsulin antihyperglycemic options to promote shared clinical decision-making
John E. Anderson, MD
John (Jack) L. Leahy, MD
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose any real or apparent conflicts of interest relating to the topics of these educational activities.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of these CME activities:
|Name of Faculty or Presenter|
Relationship Identified With:
John E. Anderson, MD
Consultant/Advisor: Abbott Diabetes Care, AstraZeneca plc, Boehringer Ingelheim GmbH, Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., sanofi-aventis U.S. LLC
Speakers’ Bureau: AstraZeneca plc, Boehringer Ingelheim GmbH, Eli Lilly and Company, Janssen Pharmaceuticals, Inc., sanofi-aventis U.S. LLC
|John (Jack) L. Leahy, MD|
Consultant/Advisor: Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk Inc., sanofi-aventis U.S. LLC, Valeritas, Inc.
Speakers’ Bureau: Merck & Co., Inc.
Non-faculty: Jim Kappler, PhD; Sandy Breslow; Alison Kemp; and Bernard M. Abrams, MD, hereby state that neither they nor their spouses/life partners have any financial relationships to products or devices with any commercial interest related to the content of these activities of any amount during the past 12 months.
This activity has been supported by an independent educational grant from Novo Nordisk Inc.
Jointly provided by the Elsevier Office of Continuing Medical Education, Dannemiller, and Integritas Communications.
CME Credit (Physicians)
These activities have been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Integritas Communications. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
The Elsevier Office of Continuing Medical Education designates each enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in each activity.
CE CREDITS (NURSING)
In support of improving patient care, this activity has been planned and implemented by Dannemiller and Elsevier Office of Continuing Medical Education. Dannemiller is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Dannemiller designates this educational activity for 0.25 contact hours.
CME Inquiries/Special Needs
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The Elsevier Office of Continuing Medical Education, Dannemiller, Integritas Communications, and Novo Nordisk Inc. do not recommend the use of any agent outside of the labeled indications.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
- 0.25 AMA PRA Category 1 Credit(s)™
- 0.25 Nursing Contact Hours
- 0.25 Non-physician